His study ties his expertise on Bone marrow together with the subject of Immunology. Peter D. Senter regularly links together related areas like Immunology in his Bone marrow studies. In his study, he carries out multidisciplinary Antibody and Complement-dependent cytotoxicity research. Peter D. Senter connects Complement-dependent cytotoxicity with Complement system in his study. Peter D. Senter conducts interdisciplinary study in the fields of Complement system and Antibody-dependent cell-mediated cytotoxicity through his works. His Antibody-dependent cell-mediated cytotoxicity study frequently draws connections between adjacent fields such as Cytotoxicity. Many of his studies involve connections with topics such as Biochemistry and Cytotoxicity. His Biochemistry study frequently draws connections to adjacent fields such as Ribosome. Peter D. Senter integrates Ribosome and Gene in his research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
Svetlana O Doronina;Brian E Toki;Michael Y Torgov;Brian A Mendelsohn.
Nature Biotechnology (2003)
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Kevin J. Hamblett;Peter D. Senter;Dana F. Chace;Michael M. C. Sun.
Clinical Cancer Research (2004)
Arming antibodies: prospects and challenges for immunoconjugates
Anna M Wu;Peter D Senter.
Nature Biotechnology (2005)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.
Joseph A Francisco;Charles G Cerveny;Damon L Meyer;Bruce J Mixan.
Monomethylvaline compounds capable of conjugation to ligands
Allen J Ebens;Brian E Toki;Mark X Sliwkowski;Paul Polakis.
Antibody–drug conjugates: targeted drug delivery for cancer
Stephen C Alley;Nicole M Okeley;Peter D Senter.
Current Opinion in Chemical Biology (2010)
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
Peter D. Senter;Mark G. Saulnier;Joseph P. Brown;David E. Kerr.
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Peter D Senter;Eric L Sievers.
Nature Biotechnology (2012)
Antibody-Drug Conjugates in Cancer Therapy
Eric L Sievers;Peter D Senter.
Annual Review of Medicine (2013)
Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity
Svetlana O. Doronina;Brian A. Mendelsohn;Tim D. Bovee;Charles G. Cerveny.
Bioconjugate Chemistry (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: